Umbilical Cord Stem Cells Calm Eczema by Blocking Neutrophil Invasion

Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin disease affecting roughly 223 million people globally. Current treatments—corticosteroids, antihistamines, biologics, and JAK inhibitors—offer incomplete relief, carry side effects, and address symptoms rather than root immune dysregulation. Mesenchymal stem cells (MSCs) have emerged as promising immunomodulatory agents, but the precise mechanisms by which umbilical cord-derived MSCs (hUC-MSCs) combat AD remained poorly understood.

This study employed two well-validated AD mouse models: one induced by DNCB (a contact sensitizer triggering delayed-type hypersensitivity) and one by OVA (an allergen driving IgE-mediated inflammation). Either hUC-MSCs (2×10⁶ cells per injection, subcutaneous) or hUC-MSC conditioned medium (hUC-MSC-CM) was administered subcutaneously during the sensitization phase. Skin histopathology, serum IgE ELISA, flow cytometry of skin-infiltrating immune cells, RNA sequencing of stimulated keratinocytes, cytokine arrays, and exosome characterization were used to measure outcomes and probe mechanisms.

Both hUC-MSCs and hUC-MSC-CM significantly reduced macroscopic AD hallmarks—erythema, scaling, and skin thickening—in both models. Histology confirmed decreased epidermal thickness and reduced immune cell infiltration. Serum IgE levels fell substantially, and neither treatment caused body-weight loss, suggesting an acceptable safety profile. Flow cytometry revealed a striking reduction in neutrophil accumulation in skin, implicating neutrophil chemotaxis as a key pathogenic axis suppressed by hUC-MSC therapy.

Mechanistic studies focused on keratinocytes (HaCaT cells) stimulated with TNF-α/IFN-γ to mimic the AD inflammatory environment. RNA sequencing and cytokine arrays demonstrated that hUC-MSC-CM significantly downregulated keratinocyte-derived chemokines, particularly CCL5 and CXCL11, both potent neutrophil chemoattractants. Exosomes isolated from hUC-MSCs recapitulated this effect, and western blotting confirmed that STAT3 phosphorylation—a master regulator of chemokine gene transcription—was inhibited. Pharmacological blockade with the STAT3 inhibitor Stattic mimicked the exosome effect, confirming the pathway's centrality. These findings establish an exosome → STAT3 suppression → reduced chemokine secretion → decreased neutrophil recruitment axis as the dominant mechanism.

The demonstration that hUC-MSC-CM alone achieves comparable efficacy to whole-cell therapy is clinically significant. Conditioned medium is easier to standardize, store, and administer, and avoids risks associated with live cell transplantation such as immune rejection or rare tumorigenic events. The mechanistic focus on neutrophils—cells increasingly recognized as early orchestrators of AD flares rather than mere bystanders—also opens new therapeutic targets. Limitations include exclusive use of mouse models (DNCB and OVA do not fully recapitulate human AD complexity), absence of human clinical data, and the need for further characterization of specific exosomal cargo (miRNAs or proteins) responsible for STAT3 inhibition.